Patents by Inventor Bruno Schoentjes
Bruno Schoentjes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11583524Abstract: The present invention provides compounds of formula (I), their use as an inhibitor of a p53-MDM2 interaction as well as pharmaceutical compositions comprising said compounds: wherein n, m, p, s, t, R1, R2, R3, R4, R5, R6, R7, R20, X, Y, Q and Z have defined meanings.Type: GrantFiled: December 18, 2019Date of Patent: February 21, 2023Assignee: Janssen Pharmaceutica NVInventors: Virginie Sophie Poncelet, Sophie Coupa, Pierre-Henri Storck, Bruno Schoentjes
-
Publication number: 20200121667Abstract: The present invention provides compounds of formula (I), their use as an inhibitor of a p53-MDM2 interaction as well as pharmaceutical compositions comprising said compounds: wherein n, m, p, s, t, R1, R2, R3, R4, R5, R6, R7, R20, X, Q and Z have defined meanings.Type: ApplicationFiled: December 18, 2019Publication date: April 23, 2020Inventors: Virginie Sophie Poncelet, Sophie Coupa, Pierre-Henri Storck, Bruno Schoentjes
-
Publication number: 20180263966Abstract: The present invention provides compounds of formula (I), their use as an inhibitor of a p53-MDM2 interaction as well as pharmaceutical compositions comprising said compounds: wherein n, m, p, s, t, R1, R2, R3, R4, R5, R6, R7, R20, X, Y, Q and Z have defined meanings.Type: ApplicationFiled: May 17, 2018Publication date: September 20, 2018Inventors: Virginie Sophie Poncelet, Sophie Coupa, Pierre-Henri Storck, Bruno Schoentjes
-
Patent number: 10017509Abstract: The present invention relates to substituted macrocylic pyrimidine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention have EF2K inhibitory activity and optionally also Vps34 inhibitory activity. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.Type: GrantFiled: April 2, 2015Date of Patent: July 10, 2018Assignee: Janssen Pharmaceutica NVInventors: Gaston Stanislas Marcella Diels, Bruno Schoentjes, Matthias Luc Aime Versele, Didier Jean-Claude Berthelot, Marc Willems, Marcel Viellevoye, Werner Constant Johan Embrechts, Berthold Wroblowski, Lieven Meerpoel
-
Patent number: 9844595Abstract: The invention relates to a gastroenteric therapeutic composition for oral administration, comprising a compound of monomeric (+)-catechin and at least one basic amino acid, said composition being characterized in that it is used in the form of a complex of (+)-catechin and at least one basic amino acid or at least one derivative or precursor of a basic amino acid for the curative and/or preventive treatment of cancer, said complex having a molar equivalence ratio of the monomeric (+)-catechin to the at least one basic amino acid or the at least one basic amino acid derivative of between 1:1 and 1:2.5.Type: GrantFiled: May 13, 2014Date of Patent: December 19, 2017Assignee: ValoreInventors: Paul Niebes, Bronislav Henric May, Saïd Rachidi, Julien Estager, Bruno Schoentjes
-
Publication number: 20170112818Abstract: The present invention provides compounds of formula (I), their use as an inhibitor of a p53-MDM2 interaction as well as pharmaceutical compositions comprising said compounds: wherein n, m, p, s, t, R1, R2, R3, R4, R5, R6, R7, R20, X, Y, Q and Z have defined meanings.Type: ApplicationFiled: January 4, 2017Publication date: April 27, 2017Inventors: Virginie Sophie Poncelet, Sophie Coupa, Pierre-Henri Storck, Bruno Schoentjes
-
Patent number: 9573933Abstract: The present invention provides compounds of formula (I), their use as an inhibitor of a p53-MDM2 interaction as well as pharmaceutical compositions comprising said compounds: wherein n, m, p, s, t, R1, R2, R3, R4, R5, R6, R7, R20, X, Y, Q and Z have defined meanings.Type: GrantFiled: September 18, 2008Date of Patent: February 21, 2017Assignee: Janssen Pharmaceutica NVInventors: Virginie Sophie Poncelet, Sophie Coupa, Pierre-Henri Storck, Bruno Schoentjes
-
Publication number: 20170022202Abstract: The present invention relates to substituted macrocylic pyrimidine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention have EF2K inhibitory activity and optionally also Vps34 inhibitory activity. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.Type: ApplicationFiled: April 2, 2015Publication date: January 26, 2017Applicant: JANSSEN PHARMACEUTICA NVInventors: Gaston Stanislas Marcella DIELS, Bruno SCHOENTJES, Matthias Luc Airné VERSELE, Didier Jean-Claude BERTHELOT, Marc WIELLEVOYE, Marcel VIELLEVOYE, Werner Constant Johan EMBRECHTS, Berthold WROBLOWSKI, Lieven MEERPOEL
-
Publication number: 20170022201Abstract: The present invention relates to substituted macrocylic pyrimidine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention have EF2K inhibitory activity and optionally also Vps34 inhibitory activity. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.Type: ApplicationFiled: April 2, 2015Publication date: January 26, 2017Applicant: JANSSEN PHARMACEUTICA NVInventors: Gaston Stanislas Marcella Diels, Bruno Schoentjes, Matthias Luc Aime Versele, Didier Jean-Claude Berthelot, Mar Willems, Marcel Viellevoye, Francois Maria Sommen, Berthold Wroblowski, Lieven Meerpoel
-
Publication number: 20160095923Abstract: The invention relates to a gastroenteric composition comprising a compound of monomeric (+)-catechin and at least one basic amino acid or at least one derivative of a basic amino acid, said compound being in the form of a complex having a molar equivalence ratio of said monomeric (+)-catechin to said at least one basic amino acid or its derivative of between 1:1 and 1:2.5, preferably between 1:1 and 1:2.Type: ApplicationFiled: May 13, 2014Publication date: April 7, 2016Applicant: VALOREInventors: Paul Niebes, Bronislav Henric May, Saïd Rachidi, Julien Estager, Bruno Schoentjes
-
Publication number: 20160089358Abstract: The invention relates to a gastroenteric therapeutic composition for oral administration, comprising a compound of monomeric (+)-catechin and at least one basic amino acid, said composition being characterized in that it is used in the form of a complex of (+)-catechin and at least one basic amino acid or at least one derivative or precursor of a basic amino acid for the curative and/or preventive treatment of cancer, said complex having a molar equivalence ratio of the monomeric (+)-catechin to the at least one basic amino acid or the at least one basic amino acid derivative of between 1:1 and 1:2.5.Type: ApplicationFiled: May 13, 2014Publication date: March 31, 2016Applicant: VALOREInventors: Paul Niebes, Bronislav Henric May, Saïd Rachidi, Julien Estager, Bruno Schoentjes
-
Patent number: 9040725Abstract: The present invention relates to a compound of formula (I) including any stereochemically isomeric form thereof, wherein the substituents are as defined in the specification and the claims; a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof; provided that the compound is other than or a pharmaceutically acceptable salt thereof. The claimed compounds are useful for the treatment of a disease, the treatment of which is affected, mediated or facilitated by activating the GHS1A-r receptor. The invention also relates to pharmaceutical compositions thereof and processes for the preparation thereof.Type: GrantFiled: March 10, 2014Date of Patent: May 26, 2015Assignee: Janssen Pharmaceutica, NVInventors: Bruno Schoentjes, Alain Philippe Poncelet, Julien Georges Pierre-Olivier Doyon, Joannes Theodorus Maria Linders, Lieven Meerpoel, Luc August Laurentius Ver Donck
-
Patent number: 8853406Abstract: The present invention provides compounds of formula (I), their use as an inhibitor of a p53-MDM2 interaction as well as pharmaceutical compositions comprising said compounds of formula (I).Type: GrantFiled: August 5, 2008Date of Patent: October 7, 2014Assignee: Janssen Pharmaceutica NVInventors: Alain Philippe Poncelet, Bruno Schoentjes, Pierre-Henri Storck, Virginie Sophie Poncelet, Carina Leys
-
Publication number: 20140187557Abstract: The present invention relates to a compound of formula (I) including any stereochemically isomeric form thereof, wherein the substituents are as defined in the specification and the claims; a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof; provided that the compound is other than or a pharmaceutically acceptable salt thereof. The claimed compounds are useful for the treatment of a disease, the treatment of which is affected, mediated or facilitated by activating the GHS1A-r receptor. The invention also relates to pharmaceutical compositions thereof and processes for the preparation thereof.Type: ApplicationFiled: March 10, 2014Publication date: July 3, 2014Applicant: Janssen Pharmaceutica NVInventors: Bruno Schoentjes, Alain Philippe Poncelet, Julien Georges Pierre-Olivier Doyon, Joannes Theodorus Maria Linders, Lieven Meerpoel, Luc August Laurentius Ver Donck
-
Patent number: 8703973Abstract: The present invention relates to a compound of formula (I) including any stereochemically isomeric form thereof, wherein the substituents are as defined in the specification and the claims; a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof; provided that the compound is other than ?or a pharmaceutically acceptable salt thereof. The claimed compounds are useful for the treatment of a disease, the treatment of which is affected, mediated or facilitated by activating the GHS1A-r receptor. The invention also relates to pharmaceutical compositions thereof and processes for the preparation thereof.Type: GrantFiled: August 29, 2012Date of Patent: April 22, 2014Assignee: Janssen Pharmaceutica NVInventors: Bruno Schoentjes, Alain Philippe Poncelet, Julien Georges Pierre-Olivier Doyon, Joannes Theodorus Maria Linders, Lieven Meerpoel, Luc August Laurentius Ver Donck
-
Patent number: 8604200Abstract: This invention concerns substituted diaza-spiro-[4.4]-nonane derivatives having neurokinin antagonistic activity, in particular NK1 antagonistic activity, their preparation, compositions comprising them and their use as a medicine, in particular for the treatment and/or prophylaxis of schizophrenia, emesis, anxiety and depression, irritable bowel syndrome (IBS), circadian rhythm disturbances, pre-eclampsia, nociception, pain, in particular visceral and neuropathic pain, pancreatitis, neurogenic inflammation, asthma, chronic obstructive pulmonary disease (COPD) and micturition disorders such as urinary incontinence. The compounds according to the invention can be represented by general Formula (I) and comprises also the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof and prodrugs thereof, wherein all substituents are defined as in claim 1.Type: GrantFiled: March 3, 2006Date of Patent: December 10, 2013Assignee: Janssen Pharmaceutica N.V.Inventors: Frans Eduard Janssens, Sophie Coupa, Alain Philippe Poncelet, Yvan Rene Ferdinand Simonnet, Bruno Schoentjes
-
Patent number: 8541442Abstract: The present invention provides compounds of formula (I), their use for the treatment of cancer as well as pharmaceutical compositions comprising said compounds of formula (I).Type: GrantFiled: February 3, 2010Date of Patent: September 24, 2013Assignee: Janssen Pharmaceutica N.V.Inventors: Bruno Schoentjes, Sophie Descamps, Nathalie Claudie Isabelle Amblard
-
Patent number: 8404683Abstract: The present invention provides compounds of formula (I), their use as an inhibitor of a p53-MDM2 interaction as well as pharmaceutical compositions comprising said compounds of formula (I) wherein n, m, p, s, t, R1, R2, R3, R4, R5, R6, R7, X, Y, Q and Z have defined meanings.Type: GrantFiled: November 3, 2010Date of Patent: March 26, 2013Assignee: Janssen Pharmaceutical N.V.Inventors: Jean Ferand Armand Lacrampe, Christophe Meyer, Yannick Aimè Eddy Ligny, Imre Christian Francis Csoka, Luc Van Hijfte, Janine Arts, Bruno Schoentjes, Camille Georges Wermuth, Bruno Giethlen, Jean-Marie Contreras, Muriel Joubert
-
Patent number: 8377961Abstract: The present invention provides compounds of formula (I), their use as an inhibitor of a p53-MDM2 interaction as well as pharmaceutical compositions comprising said compounds of formula (I) wherein n, m, p, t, R1, R2, R3, R4, R5, R6, R7, Q, Y and Z have defined meanings.Type: GrantFiled: November 30, 2011Date of Patent: February 19, 2013Assignee: Janssen Pharmaceutica N.V.Inventors: Jean Fernand Armand Lacrampe, Christophe Meyer, Bruno Schoentjes, Alain Philippe Poncelet, Camille Georges Wermuth, Bruno Giethlen, Jean-Marie Contreras, Muriel Joubert, Luc Van Hijfte
-
Publication number: 20130005769Abstract: The present invention provides compounds of formula (I), their use as an inhibitor of a p53-MDM2 interaction as well as pharmaceutical compositions comprising said compounds: wherein n, s, t, R1, R2, R3, R4, R5, X, Y, Q, Z, G, E and D have defined meanings.Type: ApplicationFiled: September 7, 2012Publication date: January 3, 2013Inventors: Pierre Henri Storck, Bruno Schoentjes, Arnaud Marcel Pierre Piettre, Philipp Ermert, Virginie Sophie Poncelet, Imre Christian Francis Csoka